International Journal of Drug Delivery Technology
Volume 14, Issue 4

Pharmacological Screening of Some Novel 3,5-Disubstituted Isoxazoles Derivatives of Dibromochalcones

Kumar V*, Rao CMMP

School of Pharmacy, Raffles University, Neemrana, Alwar Rajasthan 301705 

Received: 23rd Oct, 2024; Revised: 6th Nov, 2024; Accepted: 10th Nov, 2024; Available Online: 25th Dec, 2024

ABSTRACT

Background: The preparation of some novel 3, 5-disubstituted isoxazole derivatives of dibromochalcones is encouraged by the study. When hydroxylamine hydrochloride and α-β chalcone dibromide combine, a new technique for synthesizing 3,5-disubstituted isoxazoles is produced. Bromine or N-BromoSuccinimide can be used to produce compounds with low polarity like carbon tetrachloride, chloroform and dichloromethane; however the product obtained are very little. Tetrabutylammonium tribromide (TBABr3), thus, induces chalcones to bromate regioselectively and produces a high yield without polymerisation. TBABr3 is not toxic or corrosive, unlike bromine, and it is simple to utilise in mild circumstances. Tetrabutyl ammonium bromide and sodium bromide are dissolved in an aqueous solution at room temperature, then hydrobromic acid is added to create TBABr3.Motivated by the aforementioned information, we intended to create further isoxazole derivatives and assess their ability to reduce inflammation. Focused on a range of 3,5-disubstituted isoxazole derivatives of α-β dibromochalcones, the current study was created by reacting α-β dibromochalcones with hydroxylamine hydrochloride.

Methods: Tetrabutyl Ammonium Tribromide (TBABr3) was used to react with the corresponding chalcones to produce a high yield of α-β dibromochalcones that are regioselectively brominated without polymerisation. After this characterization, antioxidant and pharmacological qualities were assessed.

Results: Many 3,5-disubstituted isoxazoles were created by reacting hydroxylamine hydrochloride with chalcone dibromides. The substances were all characterized using elemental analysis, NMR, and IR. The product's infrared spectra revealed that the carbonyl group's peak at 1680 cm–1 was absent. A strong singlet at δ = 8.1 ppm was seen in the 1H NMR spectra. This single proton corresponded to the C (3)-H of the isoxazole ring. The ability of antioxidants to scavenge free radicals was assessed using DPPH.

Conclusion: Comparing the compounds V5I5 and V7I7 to the standard, they showed modest antioxidant activity. When the synthetic compounds were evaluated for their pharmacological activities, substances V2I2 and V4I4 outperformed the reference.

Keywords: Isoxazoles, Dibromochalcones, Substituted Isoxazoles, Tetrabutylammoniumtribromide (TBABr3), Anti- inflammatory and Antioxidant activity

How to cite this article: Kumar V, Rao CMMP. Pharmacological Screening of Some Novel 3,5-Disubstituted Isoxazoles Derivatives of Dibromochalcones. International Journal of Drug Delivery Technology. 2024;14(4):2166-71. doi: 10.25258/ijddt.14.4.30

REFERENCES

  1. Alsalameh, S, Burian, M, Mahr G, Woodcock BG, Geisslinger G. The pharmacological properties and clinical use of valdecoxib, a new cyclo-oxygenase-2- selective Aliment.    Pharmacol. Ther. 2003; 17: 489–501. DOI: 10.1046/j.1365- 2036.2003.01460.x.
  2. Fox RI, Herrmann ML, Frangou CG, Wahl GM, Morris RE, Strand V, Kirschbaum BJ. Mechanism of action for leflunomide in rheumatoid arthritis. Immunol. 1999; 93:198–208. DOI: 10.1006/clim.1999.4777
  3. Christian B. M. Poulie, Na Liu, Anders A. Jensen, Lennart Bunch. Design, Synthesis, and Pharmacological Characterization of Heterobivalent Ligands for the Putative 5-HT2A/mGlu2 Receptor Complex. Journal of Medicinal Chemistry. 2020;63 (17):9928-9949.DOI.org/10.1021/acs.jmedchem.0c01058
  4. Ryng S, Głowiak T. Nucleophilic Substitution of an Acyl Azide: General Method for the Preparation of 5- Amino-3-methyl-4-isoxazolecarboxylic Acid Amides and Synth. Commun. 1997, 27, 1359–DOI.org/10.1080/00397919708006065
  5. Ryng S, Machoń Z, Wieczorek Z, Zimecki Synthesis and immunological activity of new 5-amino- 3-methyl 4-amido and  4-ureilene   isoxazole derivatives. Pharmazie. 1999;54:359–361. DOI:10.1002/chin.199940110
  6. Ryng S, Zimecki M, Fedorowicz A, Jezierska Reactions of 5-amino-3-methylisoxazole-4-carboxylic acid hydrazide with carbonyl compounds: Immunological     activity and QSAR studies    of products. Arch.  Pharm. 2001; 334: 71–78. DOI.org/10.1002/1521-4184(200103)334:3<71::AID- ARDP71>3.0.CO;2-I
  7. Jezierska A, Mączyński M, Koll A, Ryng S. Structure activity investigations of 5-substituted 3- methylisoxazole[5, 4-d]1, 2, 3-triazin-4-one Arch. Pharm. 2004; 337: 81–89. DOI: 10.1002/ardp.200300757
  8. Ryng S, Sonnenberg Z, Zimecki M. RM-11, a new izoxasole derivative, is a potent stimulator of the humoral and cellular immune responses in mice. Arch. Immunol.   Exp. 2000; 48:  127–131.  DOI:10.3390/molecules23102724
  9. Ryng S, Machon Z, Wieczorek Z, Zimecki M, GłowiakSynthesis and    Structure    Elucidation    of 5- Aminomethinimino-3-methyl-4-isoxazolecarboxylic Acid         Phenylamides          and     Their     Immunological Activity. Arch. Pharm. 1997; 330:       319–326. DOI: 10.1002/ardp.19973301102
  10. Zimecki M, Artym J, Ryng S, Obmińska-MrukowiczRM-11, an isoxazole derivative, accelerates restoration of the immune function in mice treated with cyclophosphamide. Pharmacol. Rep. 2008; 60: 183–DOI:18443379
  11. Zimecki M, Artym J, Kocięba M, Obmińska- Mrukowicz B, Mączyński M, Ryng S. Restoration of immune system function is accelerated in immunocompromised mice by the B-cell-tropic isoxazole R-11. Rep. 2012; 64: 403–411. DOI:10.1016/s1734-1140(12)70781-8
  12. Zimecki M, Artym J, Kocięba M, Obmińska- Mrukowicz B, Mączyński M, Ryng S. Immune function in cyclophosphamide-treated mice is restored by the T-cell-tropic isoxazole derivative R-13.Immunotoxicol. 2015; 12:            322–329.            DOI: 10.3109/1547691x.2014.978486
  13. Ryng S, Zimecki M, Mączyński M, Chodaczek G, Kocięba M. Immunosuppressive activity of an isoxazolo[5,4-e]triazepine-compound RM33 I. Effects on the humoral and cellular immune response in mice. Pharmacol. 2005; 57: 195–202. DOI:10.1016/s1734-1140(12)70787-6
  14. Ryng S, Zimecki M, Mączyński M, Chodaczek G, Kocięba M. Immunosuppressory activity of an isoxazolo[5,4-e]triazepine-compound RM-33 II. Effects on the carrageenan-induced Pharmacol. Rep. 2006; 58: 236–241. DOI:10.1016/s1734-1140(12)99789-6
  15. Ryng S, Zimecki M, Mączyński M, Chodaczek G, Kocięba M. Closely related isoxazoles may exhibit opposite immunological Acta Pol. Pharm. 2008; 65: 793–794. DOI: 10.3109/1547691x.2014.878484
  16. Ryng S, Zimecki M, Mączyński M, Chodaczek G, Kocięba M. Synthesis, immunomodulating effects and structure-activity relationships of new N-phenyl-5- amino-3-methylisoxazole-4-carboxamides. J. Med. Chem. 1998; 33: 831–836. DOI: 10.1002/(sici)1521-4184(19995)332:5<158::aid-
  17. ardp158>3.0.co;2-n
  18. Ryng S, Zimecki M, Mączyński M, Chodaczek G, Kocięba M. Immunomodulating action and structure- activity relationships of substituted phenylamides of 5- amino-3-methylisoxazole-4-carboxylic Arch. Pharm. 1999; 332: 158–162. DOI: 10.1002/(sici)1521- 4184(19995)332:5<158::aid-ardp158>3.0.co;2-n
  19. Ryng S, Zimecki M, Mączyński M, Chodaczek G, Kocięba M. Koll, A. Immunological activity of new heterocyclic amides of 5-amino-3-methylisoxazole-4- carboxylic acid. J. Pharmacol. 1999; 51: 257–262. DOI: 10.3109/1547691x.2014.878484
  20. Mączyński M, Artym J, Kocięba M, Sochacka-Ćwikła A, Drozd-Szczygieł E, Ryng S, Zimecki M. Synthesis and immunoregulatory properties of selected 5-amino- 3-methyl-4-isoxazolecarboxylic acid Acta Pol. Pharm. 2016; 73: 1201–1211. DOI: 10.3390/molecules23102724
  21. Mączyński M, Zimecki M, Taraszkiewicz M, Ryng, Synthesis, immunological activity and computational study of 5-amino-3-methyl-4-isoxazolecarboxylic acid semicarbazides and thiosemicarbazides. Acta Pol. Pharm. 2008; 65: 543–549. DOI:10.3390/molecules23102723
  22. Mączyński M, Zimecki M, Taraszkiewicz M, Ryng, Structure and immunological activity of disubstituted thiosemicarbazide isoxazole derivative. Acta Pol. Pharm. 2004; 61: 82–83.   DOI:10.3390/molecules23102724
  23. Mączyński M, Zimecki M, Taraszkiewicz M, Ryng, A new class of isoxazole derivatives: The M 1-9 series of compounds with immunotropic activity. Acta Pol. Pharm. 2008; 65: 241–244. DOI: 10.3109/1547691x.2014.878484
  24. Mączyński M, Zimecki M, Taraszkiewicz M, Ryng, Jodkowski JT. New lead structures in the isoxazole system: Relationship between quantum chemical parameters and immunological activity. Acta Pol. Pharm. 2014; 71: 71–83. DOI: 10.3209/1547691x.2014.878476
  25. Shaw G, Sugowdz G. ISO Oxazolones. Part VI. The hydrogenation of 5-aminoisooxazoles. A new synthesis of J. Chem. Soc. 1954; 23: 665–668. DOI: 10.3390/molecules23071545
  26. Baba H, Hori I, Hayashi T, Midorikawa H. Reactions of α-Cyano-β-methoxy-β-alkylacrylic Esters with Hydrazine and Bull. Chem. Soc. Jpn. 1969; 42: 1653–1659.DOI:10.1002/chin.200547164
  27. Regiec A, Płoszaj P, Ryng S, Wojciechowski P. Vibrational spectroscopy of 5-amino-3-methyl-4- isoxazolecarbohydrazide and its N-deuterated isotopologue. Spectrosc. 2014; 70: 125–136. DOI:10.1016/j.vibspec.2013.11.012
  28. Regiec A, Płoszaj P, Ryng S, Wojciechowski P. Infrared spectra and other properties predictions of 5- amino-3-methyl-4-isoxazolecarbohydrazide with electric field simulation using CPC model. J. Mol. Struct. 2018, 1161, 320–338. DOI:10.3390/molecules23071545
  29. Fragoso, YD, Brooks JBB. Leflunomide and teriflunomide: Altering the metabolism of pyrimidines for the treatment of autoimmune diseases. Expert Rev. Clin. 2015; 8: 315–320. DOI: 10.1586/17512433.2015.1019343
  30. Patrick GL. An Introduction to Medicinal Chemistry; OUP Oxford: Oxford, UK, 2013; ISBN 978-0-19- 969739-7.
  31. Laufer SA, Margutti S, Fritz MD. Substituted isoxazoles as potent inhibitors of p38 MAP kinase. Med. Chem. 2006; 1: 197–207. DOI: 10.1002/cmdc.200500025
  32. Khan KM, Mughal UR, Khan MTH, Perveen S. Oxazolones: New tyrosinase inhibitors; synthesis and their structure–activity relationships. Med. Chem. 2006; 14: 6027–6033. DOI: 10.1016/j.bmc.2006.05.014
  33. Mączyński M, Artym J, Kocięba M, Kochanowska I, Ryng S, Zimecki M. Anti-inflammatory properties of an isoxazole derivative—MZO-2. Rep. 2016; 68: 894–902. DOI: 10.1016/j.pharep.2016.04.017
  34. Mukerjee N, McGinnis KM, Gnegy ME, Wang KK. Caspase-mediated calcineurin activation contributes to IL-2 release during T cell activation. Biochem. Biophys. Res. Commun. 2001; 285: 1192–1199. DOI: 1006/bbrc.2001.5278
  35. Drynda A, Obmińska-Mrukowicz B, Zaczyńska E, Zimecki M, Kochanowska I, Ryn S, Mączyński M. 5- Amino-3-methyl-4-isoxazolecarboxylic acid hydrazide derivatives with in vitro immunomodulatory activities. Biol. Drug Des. 2017; 89: 705–713. DOI: 10.1111/cbdd.12892
  36. Chaudhary PM, Eby MT, Jasmin A, Kumar A, Liu L, Hood L. Activation of the NF-kappa B pathway by caspase 8 and its Oncogene 2000; 19:4451–4460. DOI: 10.1038/sj.onc.1203812
  37. Liu F, Bardhan K, Yang D, Thangaraju M, Ganapathy V, Waller JL, Liles GB, Lee JR, Liu K. NF-κB directly regulates Fas transcription to modulate Fas-mediated apoptosis and tumor  J.  Biol.Chem. 2012; 282:               25530–25540.              DOI: 10.1074/jbc.M112.356279
  38. Mohan S, Abdelwahab SI, Kamalidehghan B, Syam S, May KS, Harmal NSM, Shafifiyaz N. Involvement of NF-κB and Bcl2/Bax signaling pathways in the apoptosis of MCF7 cells induced by a xanthone compound Pyranocycloartobiloxanthone
  39. Phytomedicine 2012; 19: 1007–1015. DOI: 10.1016/j.phymed.2012.05.012